ASCO GI: Mixed Results for Liposomal Irinotecan
SAN FRANCISCO (MedPage Today) — A randomized trial of liposomal irinotecan (PEP02) in gastric cancer yielded mixed results, achieving the primary objective of tumor shrinkage but without improving disease control rates or survival.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com